From: Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases
Age | Sex | Dose | Company | locSVT | Latency (days) | Therapy | Outcome | References |
---|---|---|---|---|---|---|---|---|
53 | f | 1st | A | Cavernous | 11 | Intubation, platelets | Death | [9] |
55 | m | 1st | A | Cavernous | 8 | Steroids, argatroban | Death | [9] |
30* | f | 1st | A | Transverse, sigmoid | 7 | Argatroban, IVIG | PR | [10] |
30 | f | 1st | A | nr | 9 | Tinzaparin, rivaroxaban | PR | [11] |
27* | m | 1st | A | nr | 2 | Dabigatran, IVIG | Death | [12] |
54* | m | nr | A | nr | 14 | Danaparoid, IVIG, DOAC | Alive | [13] |
49 | m | 1st | P | Transverse, sigmoid | 16 | Clexane, apixaban | Alive | [14] |
69 | f | 1st | A | Sigmoid, SSS | 11 | nr | Death | [5] |
32 | m | 1st | A | SSS | 9 | None | Death | [14] |
25* | m | 1st | A | SSS | 6 | Heparin, platelets, IVIG, steroids | Death | [14] |
22 | f | 1st | A | SSS, transverse | 4 | Enoxaparin, dabigatran | PR | [15] |
46 | f | 1st | A | SSS, sigmoid, transverse | 8 | Danaparoid, dabigatran | PR | [15] |
36 | f | 1st | A | SSS, straight | 7 | Enoxaparin, dabigatran | CR | [15] |
50 | m | 1st | A | Transverse, sigmoid | 7 | Craniotomy | Death | [16] |
61 | f | nr | A | nr | 14 | Enoxaparin | Discharged | [17] |
40 | m | 1st | A | nr | 14 | Enoxaparin, apixaban | Discharged | [17] |
50 | m | 1st | A | SSS, sigmoid | 7 | Enoxaparin, craniotomy | Death | [18] |
42 | f | 1st | A | SSS, straight sigmoid | 0 | Enoxaparin, craniotomy | Coma | [18] |
55 | f | 2nd | P | Straight, sigmoid | 1 | Enoxaparin | Death | [18] |
32 | f | 1st | A | Straight, sigmoid | 1 | Fondaparinux, steroids | Death | [18] |
35 | f | 1st | A | SSS, straight sigmoid | 6 | Enoxaparin, steroids, PE | Coma | [18] |
51 | f | 1st | A | Straight, sigmoid | 10 | Ventriculostomy | Death | [18] |
64 | m | 1st | A | SSS, straight, sigmoid | 4 | Enoxaparin | CR | [18] |
40 | f | 1st | A | SSS, straight sigmoid | 5 | Fondaparinux | PR | [18] |
49 | f | 1st | A | straight, sigmoid | 11 | Enoxaparin | PR | [18] |
54 | f | 1st | A | SSS, Galen | 2 | Enoxaparin, steroids | Death | [18] |
55 | f | 1st | A | Jugular | 6 | Fondaparinux craniotomy | Death | [18] |
54 | f | nr | A | Labbe, Galen | 12 | Intubation | Death | [20] |
39 | f | 1st | A | Sigmoid, transverse | 6 | Danaparoid dabigatran, IVIG | CR | [20] |
24* | f | 1st | A | Cortical | 8 | Argatroban, steroids, IVIG | CR | [21] |
32 | f | 1st | A | nr | 11 | nr | Death | [22] |
29* | m | 1st | A | Sigmoid, transverse | 9 | IVIG, agratroban | Recovery | [23] |
>40 | nr | nr | J | Transverse, sigmoid | 6 | nr | ND | [23] |
18-39 | nr | nr | J | Transverse, sigmoid | 9 | nr | Discharged | [23] |
18-39 | nr | nr | J | SSS, straight, | 8 | nr | ND | [23] |
18-39 | nr | nr | J | Transverse, sigmoid | 8 | nr | Discharged | [23] |
18-39 | nr | nr | J | Transverse, sigmoid | 6 | nr | ND | [23] |
>40 | nr | nr | J | Transverse, straight | 13 | nr | ND | [23] |
18-39 | nr | nr | J | SSS, straight, transverse | 15 | nr | ND | [23] |
18-39 | nr | nr | J | Transverse, sigmoid | 10 | nr | Discharged | [23] |
>40 | nr | nr | J | SSS, cortical | 7 | nr | ND | [23] |
18-39 | nr | nr | J | Transverse, SSS, sigmoid | 7 | nr | ND | [23] |
18-39 | nr | nr | J | Transverse, sigmoid | 11 | nr | ND | [23] |
>40 | nr | nr | J | Transverse, sigmoid | 6 | nr | Discharged | [24] |
51 | m | 1st | C | SSS, transverse | 6 | Heparin, warfarin | PR | [25] |
40 | f | 1st | J | nr | 5 | Bivalirudin | CR | [26] |
36 | f | 1st | A | SSS | 14 | Enoxaparin | Death | [27] |
25 | f | 1st | A | Cortical | 12 | nr | nr | [28] |
50* | m | 1st | A | Transverse, sigmoid | 14 | Desirudin | PR | [29] |
30* | f | 1st | A | None | 8 | Tinzaparin | PR | [11] |
ϴ46.7 (n = 45) | 35f | 1st (42) | A (n = 37) | nr | nr | nr | nr | [30] |
2nd (3) | P (n = 8) | |||||||
32-81 (n = 213) | 138 f 46 m | 1st (except 2) | P (n = 25) M (n = 1) A (n = 187) | nr | 2-21d | nr | Death (n = 46) | [31] |